{"protocolSection": {"identificationModule": {"nctId": "NCT02492763", "orgStudyIdInfo": {"id": "8521-004"}, "secondaryIdInfos": [{"id": "MK-8521-004", "type": "OTHER", "domain": "Merck protocol number"}], "organization": {"fullName": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}, "briefTitle": "A Preliminary Study of the Efficacy and Safety of MK-8521 for Type 2 Diabetes (MK-8521-004)", "officialTitle": "A Phase IIa, Multicenter, Placebo- and Active-controlled, Randomized, Double-Blind, Clinical Trial to Evaluate the Safety and Efficacy of MK-8521 Compared to Placebo in Subjects With Type 2 Diabetes Mellitus"}, "statusModule": {"statusVerifiedDate": "2018-08", "overallStatus": "TERMINATED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2015-07-27", "type": "ACTUAL"}, "primaryCompletionDateStruct": {"date": "2017-04-18", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-04-18", "type": "ACTUAL"}, "studyFirstSubmitDate": "2015-07-06", "studyFirstSubmitQcDate": "2015-07-06", "studyFirstPostDateStruct": {"date": "2015-07-09", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2018-01-18", "resultsFirstSubmitQcDate": "2018-02-07", "resultsFirstPostDateStruct": {"date": "2018-03-08", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2018-08-10", "lastUpdatePostDateStruct": {"date": "2018-09-10", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Merck Sharp & Dohme LLC", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "This is a multicenter randomized, double-blind, placebo- and active-controlled (liraglutide; Victoza\u00ae), parallel-group, clinical trial of MK-8521 in participants with type 2 diabetes mellitus (T2DM) with inadequate glycemic control while on a stable dose of metformin (\u22651000 mg/day).\n\nThe trial will include a 1-week screening period; at least an 8-week antihyperglycemic agent (AHA) washout period, if required; a 14-week blinded therapy period (which includes single-blind run-in and double-blind therapy); and a 14-day post-treatment visit, 2 weeks after the last dose of investigational product.\n\nThe primary hypothesis of the trial is that MK-8521 provides greater reduction in hemoglobin A1C relative to placebo after 12 weeks of once-daily administration in participants with T2DM with inadequate glycemic control on metformin monotherapy."}, "conditionsModule": {"conditions": ["Type II Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE2"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 176, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "MK-8521 300 \u03bcg", "type": "EXPERIMENTAL", "description": "Participants receive double-blind MK-8521 300 \u03bcg daily (QD), subcutaneously, over 12 weeks.", "interventionNames": ["Drug: MK-8521", "Drug: Placebo", "Drug: Metformin"]}, {"label": "MK-8521 180 \u03bcg", "type": "EXPERIMENTAL", "description": "Participants receive double-blind MK-8521 180 \u03bcg QD, subcutaneously, over 12 weeks.", "interventionNames": ["Drug: MK-8521", "Drug: Placebo", "Drug: Metformin"]}, {"label": "Placebo", "type": "PLACEBO_COMPARATOR", "description": "Participants receive matching double-blind placebo, QD over 12 weeks.", "interventionNames": ["Drug: Placebo", "Drug: Metformin"]}, {"label": "Liraglutide 1.8 mg", "type": "ACTIVE_COMPARATOR", "description": "Participants receive open-label 1.8 mg of liraglutide, QD, subcutaneously, over 12 weeks.", "interventionNames": ["Drug: Liraglutide", "Drug: Metformin"]}], "interventions": [{"type": "DRUG", "name": "MK-8521", "description": "Dose strengths: 180 \u03bcg QD administered subcutaneously. A 2-step dose escalation regimen \\[60 \u03bcg, 120 \u03bcg\\] over the first 2 weeks is used to achieve the final dose up to 180 \u03bcg.); 300 \u03bcg QD administered subcutaneously (A 3-step dose escalation regimen \\[60 \u03bcg, 120 \u03bcg, 180 \u03bcg\\] over the first 3 weeks is used to achieve the final dose up to 300 \u03bcg.", "armGroupLabels": ["MK-8521 180 \u03bcg", "MK-8521 300 \u03bcg"]}, {"type": "DRUG", "name": "Placebo", "description": "Double dummy matching placebo for the MK-8521 and placebo arms: matching placebo for MK-8521 300 \u03bcg QD administered subcutaneously; matching placebo for MK-8521 180 \u03bcg QD administered subcutaneously. A dose escalation regimen consistent with that of the MK-8521 300 \u03bcg and 180 \u03bcg arms of the study; mock escalation will be performed over the first 2 to 3 weeks.", "armGroupLabels": ["MK-8521 180 \u03bcg", "MK-8521 300 \u03bcg", "Placebo"]}, {"type": "DRUG", "name": "Liraglutide", "description": "Dose strength: 1.8 mg QD administered subcutaneously. A 2-step dose escalation regimen (0.6 mg, 1.2 mg) over the first 2 weeks is used to achieve the final dose up to 1.8 mg.", "armGroupLabels": ["Liraglutide 1.8 mg"], "otherNames": ["Victoza\u00ae"]}, {"type": "DRUG", "name": "Metformin", "description": "Metformin immediate release (IR) or metformin extended release (XR) administered \u22651000 mg QD as background therapy", "armGroupLabels": ["Liraglutide 1.8 mg", "MK-8521 180 \u03bcg", "MK-8521 300 \u03bcg", "Placebo"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Hemoglobin A1C (A1C) at Week 12", "description": "A1C is the percentage of hemoglobin that has glucose bound to it and is a blood marker used to report average blood glucose levels over prolonged periods of time. A1C is reported as a percentage (%). This change from baseline reflects the Week 12 A1C minus the Week 0 A1C.", "timeFrame": "Baseline and Week 12"}, {"measure": "Number of Participants With an Adverse Event (AE)", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.", "timeFrame": "Up to Week 14"}, {"measure": "Number of Participants Who Discontinued Study Treatment Due to an AE", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.", "timeFrame": "Up to Week 12"}, {"measure": "Number of Participants With an AE of Symptomatic Hypoglycemia", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Hypoglycemia episodes are those with glucose values \u226470 mg/dL (3.9 mmol/L). Symptomatic hypoglycemia episodes were episodes with clinical symptoms reported by the investigator as hypoglycemia and classified as adverse events.", "timeFrame": "Up to Week 14"}, {"measure": "Change From Baseline in Heart Rate at Week 12", "description": "This change from baseline reflects the Week 12 heart rate minus the Week 0 heart rate.", "timeFrame": "Baseline and Week 12"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Body Weight at Week 12", "description": "This change from baseline reflects the Week 12 body weight minus the Week 0 body weight.", "timeFrame": "Baseline and Week 12"}, {"measure": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12", "description": "This change from baseline reflects the Week 12 FPG minus the Week 0 FPG.", "timeFrame": "Baseline and Week 12"}, {"measure": "Change From Baseline in Fasting Low Density Lipoprotein (LDL) Cholesterol at Week 12", "description": "This change from baseline reflects the Week 12 fasting LDL cholesterol minus the Week 0 fasting LDL cholesterol.", "timeFrame": "Baseline and Week 12"}, {"measure": "Change From Baseline in Fasting High Density Lipoprotein (HDL) Cholesterol at Week 12", "description": "This change from baseline reflects the Week 12 fasting HDL cholesterol minus the Week 0 fasting HDL cholesterol.", "timeFrame": "Baseline and Week 12"}, {"measure": "Change From Baseline in Fasting Triglycerides at Week 12", "description": "This change from baseline reflects the Week 12 fasting triglycerides minus the Week 0 fasting triglycerides.", "timeFrame": "Baseline and Week 12"}, {"measure": "Change From Baseline in Systolic Blood Pressure (SBP) at Week 12", "description": "This change from baseline reflects the Week 12 SBP minus the Week 0 SBP.", "timeFrame": "Baseline and Week 12"}, {"measure": "Change From Baseline in Diastolic Blood Pressure (DBP) at Week 12", "description": "This change from baseline reflects the Week 12 DBP minus the Week 0 DBP.", "timeFrame": "Baseline and Week 12"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Have T2DM in accordance with American Diabetes Association guidelines\n* Be on metformin monotherapy (\\>-1000 mg/day: metformin IR or metformin XR) for at least 12 weeks prior to study start with a hemoglobin A1C (A1C) \\>-7.5 and \\<-10.5% OR Be on dual therapy with metformin (\\>-1000 mg/day: dose stable for at least 4 weeks prior to study start) with an A1C of \\>-7.0% and \\<-10.0% and a second AHA and be willing to washout the second AHA. Allowable AHAs are dipeptidyl peptidase 4 (DPP-4 inhibitors), alpha-glucosidase inhibitors, sulfonylureas, and glinides.\n* Have a body mass index (BMI) \u226523 kg/m\\^2 and \u226440 kg/m\\^2\n* Is a female who is not of reproductive potential, or is a female of reproductive potential who agrees to avoid becoming pregnant: while receiving study drug and for 14 days after the last dose of study drug\n\nExclusion Criteria:\n\n* Have a history of type 1 diabetes or a history of diabetic ketoacidosis\n* Has a history of other specific types of diabetes (e.g., genetic syndromes, secondary pancreatic diabetes, diabetes due to endocrinopathies, drug- or chemical-induced, and post-organ transplant)\n* Has been treated with any gut-derived incretin hormone glucagon-like peptide 1 (GLP-1) receptor agonist (e.g. Byetta\u2122, Victoza\u2122 or investigational agents) within the last 6 months or has had GLP-1 receptor agonist discontinued due to gastrointestinal intolerance or lack of efficacy. Note: treatment with a GLP-1 receptor agonist that was discontinued \\>6 months prior to study start is not an exclusion if the GLP-1 receptor agonist was discontinued for reasons other than gastrointestinal intolerance or lack of efficacy.\n* Has a history of clinically significant gastrointestinal disorder (including diabetic gastroparesis; irritable bowel disease; recurrent episodes of nausea, vomiting, diarrhea and abdominal pain)\n* Has a history of clinically significant and active, immunological, respiratory, genitourinary or major neurological (including stroke, transient ischemic attack and chronic seizures) abnormalities or diseases\n* Has a history of cardiovascular disease (including diabetic cardiomyopathy) or significant cardiac condition (including a history of myocardial infarction, stable or unstable angina, arterial revascularization, pathologic, symptomatic or sustained tachyarrhythmia \\[e.g. atrial fibrillation, sustained supraventricular tachycardia, symptomatic non-sustained supraventricular tachycardia, ventricular tachycardia, ventricular fibrillation, Wolf-Parkinson-White syndrome, congenital long QT syndrome, etc.\\]) or heart failure\n* Has a family history of medullary carcinoma of the thyroid or multiple endocrine neoplasm type-2 syndrome\n* Has active diabetic proliferative retinopathy or a history of maculopathy\n* Has human immunodeficiency virus (HIV)\n* Has a medical history of active liver disease (other than non-alcoholic hepatic steatosis), including chronic hepatitis B or C (assessed by medical history), primary biliary cirrhosis, or active symptomatic gallbladder disease\n* Is on a weight loss medication or has undergone bariatric surgery\n* Has a history of acute or chronic pancreatitis of any etiology\n* Had an event of severe hypoglycemia with neuroglycopenia in the past 12 months\n* Has a positive urine pregnancy test\n* Is pregnant or breast-feeding, or is planning to conceive during the trial, including 14 days following the last dose of investigational product\n* Routinely consumes \\>1 alcoholic drinks per day or \\>7 alcoholic drinks per week or engages in binge drinking\n* Routinely consumes \u2265480mg /day caffeine in caffeinated beverages (1 cup of coffee contains approximately 120 mg of caffeine\n* Is taking a beta blocker or medications with sympathomimetic activity (e.g. pseudoephedrine, phenylpropanolamine, etc.)\n* Is currently a user of nicotine or nicotine containing products or does not agree to refrain from using nicotine during the trial, including 14 days following the last dose of investigational product\n* Is currently a user of any illicit drugs (including any marijuana use) or has a history of drug (including alcohol) abuse within approximately 5 years\n* has other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or blinded investigational product administration", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "21 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Medical Director", "affiliation": "Merck Sharp & Dohme LLC", "role": "STUDY_DIRECTOR"}]}, "ipdSharingStatementModule": {"ipdSharing": "YES", "description": "https://www.merck.com/clinical-trials/pdf/ProcedureAccessClinicalTrialData.pdf", "url": "http://engagezone.msd.com/ds_documentation.php"}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "This study was conducted at 84 clinical trial sites in Australia, Colombia, Guatemala, Israel, Spain, New Zealand, and in the United States. Five hundred participants were screened and 176 randomized.", "groups": [{"id": "FG000", "title": "MK-8521 180 \u03bcg", "description": "Participants receive double-blind MK-8521 180 \u03bcg daily (QD), subcutaneously, over 12 weeks."}, {"id": "FG001", "title": "MK-8521 300 \u03bcg", "description": "Participants receive double-blind MK-8521 300 \u03bcg, QD, subcutaneously, over 12 weeks."}, {"id": "FG002", "title": "Placebo", "description": "Participants receive matching double-blind placebo QD over 12 weeks."}, {"id": "FG003", "title": "Liraglutide 1.8 mg", "description": "Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "46"}, {"groupId": "FG001", "numSubjects": "44"}, {"groupId": "FG002", "numSubjects": "43"}, {"groupId": "FG003", "numSubjects": "43"}]}, {"type": "Treated", "achievements": [{"groupId": "FG000", "numSubjects": "46"}, {"groupId": "FG001", "numSubjects": "44"}, {"groupId": "FG002", "numSubjects": "43"}, {"groupId": "FG003", "numSubjects": "42"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "30"}, {"groupId": "FG001", "numSubjects": "29"}, {"groupId": "FG002", "numSubjects": "33"}, {"groupId": "FG003", "numSubjects": "30"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "16"}, {"groupId": "FG001", "numSubjects": "15"}, {"groupId": "FG002", "numSubjects": "10"}, {"groupId": "FG003", "numSubjects": "13"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Hyperglycemia Discontinuation Criteria", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Non-Compliance With Study Drug", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "0"}]}, {"type": "Screen Failure", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Study Terminated by Sponsor", "reasons": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "6"}, {"groupId": "FG003", "numSubjects": "10"}]}]}]}, "baselineCharacteristicsModule": {"populationDescription": "All participants randomized", "groups": [{"id": "BG000", "title": "MK-8521 180 \u03bcg", "description": "Participants receive double-blind MK-8521 180 \u03bcg daily (QD), subcutaneously, over 12 weeks."}, {"id": "BG001", "title": "MK-8521 300 \u03bcg", "description": "Participants receive double-blind MK-8521 300 \u03bcg, QD, subcutaneously, over 12 weeks."}, {"id": "BG002", "title": "Placebo", "description": "Participants receive matching double-blind placebo QD over 12 weeks."}, {"id": "BG003", "title": "Liraglutide 1.8 mg", "description": "Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks."}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "46"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "43"}, {"groupId": "BG003", "value": "43"}, {"groupId": "BG004", "value": "176"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Years", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "46"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "43"}, {"groupId": "BG003", "value": "43"}, {"groupId": "BG004", "value": "176"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "54.0", "spread": "7.6"}, {"groupId": "BG001", "value": "54.2", "spread": "7.9"}, {"groupId": "BG002", "value": "51.5", "spread": "10.1"}, {"groupId": "BG003", "value": "52.9", "spread": "9.4"}, {"groupId": "BG004", "value": "53.2", "spread": "8.8"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "46"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "43"}, {"groupId": "BG003", "value": "43"}, {"groupId": "BG004", "value": "176"}]}], "categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "26"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "24"}, {"groupId": "BG003", "value": "20"}, {"groupId": "BG004", "value": "88"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "20"}, {"groupId": "BG001", "value": "26"}, {"groupId": "BG002", "value": "19"}, {"groupId": "BG003", "value": "23"}, {"groupId": "BG004", "value": "88"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "46"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "43"}, {"groupId": "BG003", "value": "43"}, {"groupId": "BG004", "value": "176"}]}], "categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "4"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "4"}, {"groupId": "BG004", "value": "13"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "3"}, {"groupId": "BG002", "value": "4"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "9"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "8"}, {"groupId": "BG001", "value": "9"}, {"groupId": "BG002", "value": "12"}, {"groupId": "BG003", "value": "7"}, {"groupId": "BG004", "value": "36"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "27"}, {"groupId": "BG001", "value": "25"}, {"groupId": "BG002", "value": "23"}, {"groupId": "BG003", "value": "31"}, {"groupId": "BG004", "value": "106"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "2"}, {"groupId": "BG003", "value": "1"}, {"groupId": "BG004", "value": "12"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}, {"groupId": "BG004", "value": "0"}]}]}]}, {"title": "Hemoglobin A1C Classification by Levels", "description": "Hemoglobin A1C classification by levels: \\<8.5% or \\>=8.5%", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "<8.5%", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "46"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "43"}, {"groupId": "BG003", "value": "43"}, {"groupId": "BG004", "value": "176"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "22"}, {"groupId": "BG001", "value": "24"}, {"groupId": "BG002", "value": "24"}, {"groupId": "BG003", "value": "21"}, {"groupId": "BG004", "value": "91"}]}]}, {"title": ">=8.5%", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "46"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "43"}, {"groupId": "BG003", "value": "43"}, {"groupId": "BG004", "value": "176"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "24"}, {"groupId": "BG001", "value": "20"}, {"groupId": "BG002", "value": "19"}, {"groupId": "BG003", "value": "22"}, {"groupId": "BG004", "value": "85"}]}]}]}, {"title": "Antihyperglycemic agent (AHA) Washout Status", "description": "AHA washout status (yes/no). The trial included an 8-week AHA washout period for participants taking a AHA.", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "Yes", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "46"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "43"}, {"groupId": "BG003", "value": "43"}, {"groupId": "BG004", "value": "176"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "5"}, {"groupId": "BG003", "value": "5"}, {"groupId": "BG004", "value": "20"}]}]}, {"title": "No", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "46"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "43"}, {"groupId": "BG003", "value": "43"}, {"groupId": "BG004", "value": "176"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "41"}, {"groupId": "BG001", "value": "39"}, {"groupId": "BG002", "value": "38"}, {"groupId": "BG003", "value": "38"}, {"groupId": "BG004", "value": "156"}]}]}]}, {"title": "Body Mass Index (BMI)", "description": "Number of participants with a BMI \\<30 kg/m\\^2 or BMI\\>=30 kg/m\\^2", "paramType": "NUMBER", "unitOfMeasure": "Participants", "classes": [{"title": "<30 kg/m^2", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "46"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "43"}, {"groupId": "BG003", "value": "43"}, {"groupId": "BG004", "value": "176"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "14"}, {"groupId": "BG002", "value": "15"}, {"groupId": "BG003", "value": "15"}, {"groupId": "BG004", "value": "62"}]}]}, {"title": ">=30 kg/m^2", "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "46"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "43"}, {"groupId": "BG003", "value": "43"}, {"groupId": "BG004", "value": "176"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "28"}, {"groupId": "BG001", "value": "30"}, {"groupId": "BG002", "value": "28"}, {"groupId": "BG003", "value": "28"}, {"groupId": "BG004", "value": "114"}]}]}]}, {"title": "Heart Rate", "populationDescription": "All randomized participants who had a baseline heart rate value.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Beats/minute", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "46"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "43"}, {"groupId": "BG003", "value": "42"}, {"groupId": "BG004", "value": "175"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "72.5", "spread": "7.7"}, {"groupId": "BG001", "value": "72.2", "spread": "9.9"}, {"groupId": "BG002", "value": "73.8", "spread": "8.6"}, {"groupId": "BG003", "value": "74.7", "spread": "8.9"}, {"groupId": "BG004", "value": "73.3", "spread": "8.8"}]}]}]}, {"title": "Fasting Plasma Glucose (FPG)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "46"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "43"}, {"groupId": "BG003", "value": "43"}, {"groupId": "BG004", "value": "176"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "171.4", "spread": "41.0"}, {"groupId": "BG001", "value": "175.0", "spread": "49.5"}, {"groupId": "BG002", "value": "172.0", "spread": "39.2"}, {"groupId": "BG003", "value": "187.5", "spread": "44.9"}, {"groupId": "BG004", "value": "176.4", "spread": "43.9"}]}]}]}, {"title": "Fasting Low Density Lipoprotein (LDL) Cholesterol", "populationDescription": "All randomized participants who had a baseline fasting LDL cholesterol value.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "42"}, {"groupId": "BG001", "value": "41"}, {"groupId": "BG002", "value": "40"}, {"groupId": "BG003", "value": "40"}, {"groupId": "BG004", "value": "163"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "103.3", "spread": "28.1"}, {"groupId": "BG001", "value": "95.6", "spread": "33.8"}, {"groupId": "BG002", "value": "100.5", "spread": "42.8"}, {"groupId": "BG003", "value": "93.0", "spread": "29.5"}, {"groupId": "BG004", "value": "98.2", "spread": "33.9"}]}]}]}, {"title": "Fasting High Density Lipoprotein (HDL) Cholesterol", "populationDescription": "All randomized participants who had a baseline fasting HDL cholesterol value.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "42"}, {"groupId": "BG001", "value": "41"}, {"groupId": "BG002", "value": "40"}, {"groupId": "BG003", "value": "40"}, {"groupId": "BG004", "value": "163"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "47.4", "spread": "12.3"}, {"groupId": "BG001", "value": "41.7", "spread": "9.5"}, {"groupId": "BG002", "value": "43.1", "spread": "12.0"}, {"groupId": "BG003", "value": "46.8", "spread": "13.8"}, {"groupId": "BG004", "value": "44.8", "spread": "12.1"}]}]}]}, {"title": "Fasting Triglycerides", "populationDescription": "All randomized participants who had a baseline fasting triglycerides value.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mg/dL", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "46"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "43"}, {"groupId": "BG003", "value": "42"}, {"groupId": "BG004", "value": "175"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "171.5", "spread": "104.6"}, {"groupId": "BG001", "value": "167.1", "spread": "79.5"}, {"groupId": "BG002", "value": "168.7", "spread": "96.1"}, {"groupId": "BG003", "value": "154.0", "spread": "89.5"}, {"groupId": "BG004", "value": "165.5", "spread": "92.5"}]}]}]}, {"title": "Systolic Blood Pressure (SBP)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mm Hg", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "46"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "43"}, {"groupId": "BG003", "value": "43"}, {"groupId": "BG004", "value": "176"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "125.1", "spread": "10.8"}, {"groupId": "BG001", "value": "126.0", "spread": "12.0"}, {"groupId": "BG002", "value": "124.6", "spread": "14.3"}, {"groupId": "BG003", "value": "126.3", "spread": "11.0"}, {"groupId": "BG004", "value": "125.5", "spread": "12.0"}]}]}]}, {"title": "Diastolic Blood Pressure (DBP)", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "mm Hg", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "46"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "43"}, {"groupId": "BG003", "value": "43"}, {"groupId": "BG004", "value": "176"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "76.6", "spread": "6.3"}, {"groupId": "BG001", "value": "77.9", "spread": "7.4"}, {"groupId": "BG002", "value": "77.6", "spread": "8.3"}, {"groupId": "BG003", "value": "78.9", "spread": "5.7"}, {"groupId": "BG004", "value": "77.7", "spread": "7.0"}]}]}]}, {"title": "Hemoglobin A1C", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Percent", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "46"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "43"}, {"groupId": "BG003", "value": "43"}, {"groupId": "BG004", "value": "176"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "8.54", "spread": "0.82"}, {"groupId": "BG001", "value": "8.43", "spread": "0.78"}, {"groupId": "BG002", "value": "8.46", "spread": "0.83"}, {"groupId": "BG003", "value": "8.72", "spread": "1.03"}, {"groupId": "BG004", "value": "8.54", "spread": "0.87"}]}]}]}, {"title": "Body Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "Kilograms", "classes": [{"denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "46"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "43"}, {"groupId": "BG003", "value": "43"}, {"groupId": "BG004", "value": "176"}]}], "categories": [{"measurements": [{"groupId": "BG000", "value": "85.4", "spread": "18.1"}, {"groupId": "BG001", "value": "89.4", "spread": "20.0"}, {"groupId": "BG002", "value": "90.2", "spread": "19.0"}, {"groupId": "BG003", "value": "92.4", "spread": "16.5"}, {"groupId": "BG004", "value": "89.3", "spread": "18.5"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Hemoglobin A1C (A1C) at Week 12", "description": "A1C is the percentage of hemoglobin that has glucose bound to it and is a blood marker used to report average blood glucose levels over prolonged periods of time. A1C is reported as a percentage (%). This change from baseline reflects the Week 12 A1C minus the Week 0 A1C.", "populationDescription": "All randomized, treated participants with at least one A1C measurement (baseline or post-baseline).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Percent", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "MK-8521 180 \u03bcg", "description": "Participants receive double-blind MK-8521 180 \u03bcg daily (QD), subcutaneously, over 12 weeks."}, {"id": "OG001", "title": "MK-8521 300 \u03bcg", "description": "Participants receive double-blind MK-8521 300 \u03bcg, QD, subcutaneously, over 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Participants receive matching double-blind placebo QD over 12 weeks."}, {"id": "OG003", "title": "Liraglutide 1.8 mg", "description": "Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "44"}, {"groupId": "OG002", "value": "43"}, {"groupId": "OG003", "value": "42"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.82", "lowerLimit": "-1.16", "upperLimit": "-0.49"}, {"groupId": "OG001", "value": "-1.05", "lowerLimit": "-1.41", "upperLimit": "-0.69"}, {"groupId": "OG002", "value": "-0.44", "lowerLimit": "-0.80", "upperLimit": "-0.08"}, {"groupId": "OG003", "value": "-1.42", "lowerLimit": "-1.77", "upperLimit": "-1.07"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.126", "statisticalMethod": "Longitudinal data analysis", "statisticalComment": "Terms for treatment, time, A1C (\\<8.5%, \u22658.5%), BMI (\\<30 kg/m\\^2, \u226530 kg/m\\^2) and AHA washout status (Yes, No), and the interaction of time by treatment", "paramType": "Difference in Least Squares Means", "paramValue": "-0.39", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.88", "ciUpperLimit": "0.11"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.017", "statisticalMethod": "Longitudinal data analysis", "statisticalComment": "Terms for treatment, time, A1C (\\<8.5%, \u22658.5%), BMI (\\<30 kg/m\\^2, \u226530 kg/m\\^2) and AHA washout status (Yes, No), and the interaction of time by treatment", "paramType": "Difference in Least Squares Means", "paramValue": "0.60", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.11", "ciUpperLimit": "1.08"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.018", "statisticalMethod": "Longitudinal data analysis", "statisticalComment": "Terms for treatment, time, A1C (\\<8.5%, \u22658.5%), BMI (\\<30 kg/m\\^2, \u226530 kg/m\\^2) and AHA washout status (Yes, No), and the interaction of time by treatment", "paramType": "Difference in Least Squares Means", "paramValue": "-0.61", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.12", "ciUpperLimit": "-0.10"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.146", "statisticalMethod": "Longitudinal data analysis", "statisticalComment": "Terms for treatment, time, A1C (\\<8.5%, \u22658.5%), BMI (\\<30 kg/m\\^2, \u226530 kg/m\\^2) and AHA washout status (Yes, No), and the interaction of time by treatment", "paramType": "Difference in Least Squares Means", "paramValue": "0.37", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.13", "ciUpperLimit": "0.87"}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "pValueComment": "Terms for treatment, time, A1C (\\<8.5%, \u22658.5%), BMI (\\<30 kg/m\\^2, \u226530 kg/m\\^2) and AHA washout status (Yes, No), and the interaction of time by treatment", "statisticalMethod": "Longitudinal data analysis", "paramType": "Difference in the Least Squares Means", "paramValue": "-0.98", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.49", "ciUpperLimit": "-0.48"}]}, {"type": "PRIMARY", "title": "Number of Participants With an Adverse Event (AE)", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.", "populationDescription": "All randomized participants who received at least 1 dose of study treatment.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to Week 14", "groups": [{"id": "OG000", "title": "MK-8521 180 \u03bcg", "description": "Participants receive double-blind MK-8521 180 \u03bcg daily (QD), subcutaneously, over 12 weeks."}, {"id": "OG001", "title": "MK-8521 300 \u03bcg", "description": "Participants receive double-blind MK-8521 300 \u03bcg, QD, subcutaneously, over 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Participants receive matching double-blind placebo QD over 12 weeks."}, {"id": "OG003", "title": "Liraglutide 1.8 mg", "description": "Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "44"}, {"groupId": "OG002", "value": "43"}, {"groupId": "OG003", "value": "42"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "24"}, {"groupId": "OG001", "value": "29"}, {"groupId": "OG002", "value": "25"}, {"groupId": "OG003", "value": "22"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants Who Discontinued Study Treatment Due to an AE", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study.", "populationDescription": "All randomized participants who received at least 1 dose of study treatment.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to Week 12", "groups": [{"id": "OG000", "title": "MK-8521 180 \u03bcg", "description": "Participants receive double-blind MK-8521 180 \u03bcg daily (QD), subcutaneously, over 12 weeks."}, {"id": "OG001", "title": "MK-8521 300 \u03bcg", "description": "Participants receive double-blind MK-8521 300 \u03bcg, QD, subcutaneously, over 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Participants receive matching double-blind placebo QD over 12 weeks."}, {"id": "OG003", "title": "Liraglutide 1.8 mg", "description": "Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "44"}, {"groupId": "OG002", "value": "43"}, {"groupId": "OG003", "value": "42"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "3"}, {"groupId": "OG001", "value": "1"}, {"groupId": "OG002", "value": "2"}, {"groupId": "OG003", "value": "2"}]}]}]}, {"type": "PRIMARY", "title": "Number of Participants With an AE of Symptomatic Hypoglycemia", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. Hypoglycemia episodes are those with glucose values \u226470 mg/dL (3.9 mmol/L). Symptomatic hypoglycemia episodes were episodes with clinical symptoms reported by the investigator as hypoglycemia and classified as adverse events.", "populationDescription": "All randomized participants who received at least 1 dose of study treatment.", "reportingStatus": "POSTED", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "timeFrame": "Up to Week 14", "groups": [{"id": "OG000", "title": "MK-8521 180 \u03bcg", "description": "Participants receive double-blind MK-8521 180 \u03bcg daily (QD), subcutaneously, over 12 weeks."}, {"id": "OG001", "title": "MK-8521 300 \u03bcg", "description": "Participants receive double-blind MK-8521 300 \u03bcg, QD, subcutaneously, over 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Participants receive matching double-blind placebo QD over 12 weeks."}, {"id": "OG003", "title": "Liraglutide 1.8 mg", "description": "Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "44"}, {"groupId": "OG002", "value": "43"}, {"groupId": "OG003", "value": "42"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "2"}, {"groupId": "OG002", "value": "1"}, {"groupId": "OG003", "value": "1"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.301", "statisticalMethod": "Miettinen & Nurminen method", "paramType": "Difference in % vs Placebo", "paramValue": "-2.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-12.1", "ciUpperLimit": "5.6"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.573", "statisticalMethod": "Miettinen & Nurminen method", "paramType": "Difference in % vs Placebo", "paramValue": "2.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.1", "ciUpperLimit": "13.2"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.295", "statisticalMethod": "Miettinen & Nurminen method", "paramType": "Difference in % vs Liraglutide", "paramValue": "-2.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-12.4", "ciUpperLimit": "5.5"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.587", "statisticalMethod": "Miettinen & Nurminen method", "paramType": "Difference in % vs Liraglutide", "paramValue": "2.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.4", "ciUpperLimit": "13.2"}]}, {"type": "PRIMARY", "title": "Change From Baseline in Heart Rate at Week 12", "description": "This change from baseline reflects the Week 12 heart rate minus the Week 0 heart rate.", "populationDescription": "All randomized, treated participants with at least one heart rate measurement (baseline or post-baseline).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Beats/minute", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "MK-8521 180 \u03bcg", "description": "Participants receive double-blind MK-8521 180 \u03bcg daily (QD), subcutaneously, over 12 weeks."}, {"id": "OG001", "title": "MK-8521 300 \u03bcg", "description": "Participants receive double-blind MK-8521 300 \u03bcg, QD, subcutaneously, over 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Participants receive matching double-blind placebo QD over 12 weeks."}, {"id": "OG003", "title": "Liraglutide 1.8 mg", "description": "Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "44"}, {"groupId": "OG002", "value": "43"}, {"groupId": "OG003", "value": "42"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "5.47", "lowerLimit": "2.99", "upperLimit": "7.96"}, {"groupId": "OG001", "value": "6.28", "lowerLimit": "3.72", "upperLimit": "8.84"}, {"groupId": "OG002", "value": "-1.42", "lowerLimit": "-3.92", "upperLimit": "1.07"}, {"groupId": "OG003", "value": "1.63", "lowerLimit": "-0.88", "upperLimit": "4.14"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "paramType": "Difference in the LS Means vs. Placebo", "paramValue": "6.90", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "3.42", "ciUpperLimit": "10.37", "estimateComment": "Terms for treatment, time, A1C (\\<8.5%, \u22658.5%), BMI (\\<30 kg/m\\^2, \u226530 kg/m\\^2) and AHA washout status (Yes, No), and the interaction of time by treatment", "otherAnalysisDescription": "Longitudinal data analysis"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY", "paramType": "Difference in LS Means vs. Liraglutide", "paramValue": "3.84", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "0.35", "ciUpperLimit": "7.33", "estimateComment": "Terms for treatment, time, A1C (\\<8.5%, \u22658.5%), BMI (\\<30 kg/m\\^2, \u226530 kg/m\\^2) and AHA washout status (Yes, No), and the interaction of time by treatment", "otherAnalysisDescription": "Longitudinal data analysis"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "paramType": "Difference in LS Means vs. Placebo", "paramValue": "7.70", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "4.17", "ciUpperLimit": "11.23", "estimateComment": "Terms for treatment, time, A1C (\\<8.5%, \u22658.5%), BMI (\\<30 kg/m\\^2, \u226530 kg/m\\^2) and AHA washout status (Yes, No), and the interaction of time by treatment", "otherAnalysisDescription": "Longitudinal data analysis"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY", "paramType": "Difference in LS Means vs. Liraglutide", "paramValue": "4.65", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "1.11", "ciUpperLimit": "8.19", "estimateComment": "Terms for treatment, time, A1C (\\<8.5%, \u22658.5%), BMI (\\<30 kg/m\\^2, \u226530 kg/m\\^2) and AHA washout status (Yes, No), and the interaction of time by treatment", "otherAnalysisDescription": "Longitudinal data analysis"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Body Weight at Week 12", "description": "This change from baseline reflects the Week 12 body weight minus the Week 0 body weight.", "populationDescription": "All randomized, treated participants with at least one body weight measurement (baseline or post-baseline).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "Kilograms", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "MK-8521 180 \u03bcg", "description": "Participants receive double-blind MK-8521 180 \u03bcg daily (QD), subcutaneously, over 12 weeks."}, {"id": "OG001", "title": "MK-8521 300 \u03bcg", "description": "Participants receive double-blind MK-8521 300 \u03bcg, QD, subcutaneously, over 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Participants receive matching double-blind placebo QD over 12 weeks."}, {"id": "OG003", "title": "Liraglutide 1.8 mg", "description": "Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "44"}, {"groupId": "OG002", "value": "43"}, {"groupId": "OG003", "value": "42"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.0", "lowerLimit": "-2.9", "upperLimit": "-1.1"}, {"groupId": "OG001", "value": "-3.0", "lowerLimit": "-4.0", "upperLimit": "-2.1"}, {"groupId": "OG002", "value": "-1.3", "lowerLimit": "-2.2", "upperLimit": "-0.3"}, {"groupId": "OG003", "value": "-2.9", "lowerLimit": "-3.8", "upperLimit": "-1.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.285", "statisticalMethod": "Longitudinal data analysis", "statisticalComment": "Terms for treatment, time, A1C (\\<8.5%, \u22658.5%), BMI (\\<30 kg/m\\^2, \u226530 kg/m\\^2) and AHA washout status (Yes, No), and the interaction of time by treatment", "paramType": "Difference in Least Squares Means", "paramValue": "-0.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.0", "ciUpperLimit": "0.6"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.183", "statisticalMethod": "Longitudinal data analysis", "statisticalComment": "Terms for treatment, time, A1C (\\<8.5%, \u22658.5%), BMI (\\<30 kg/m\\^2, \u226530 kg/m\\^2) and AHA washout status (Yes, No), and the interaction of time by treatment", "paramType": "Difference in Least Squares Means", "paramValue": "0.9", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-0.4", "ciUpperLimit": "2.2"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.010", "statisticalMethod": "Longitudinal data analysis", "statisticalComment": "Terms for treatment, time, A1C (\\<8.5%, \u22658.5%), BMI (\\<30 kg/m\\^2, \u226530 kg/m\\^2) and AHA washout status (Yes, No), and the interaction of time by treatment", "paramType": "Difference in Least Squares Means", "paramValue": "-1.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.1", "ciUpperLimit": "-0.4"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.811", "statisticalMethod": "Longitudinal data analysis", "statisticalComment": "Terms for treatment, time, A1C (\\<8.5%, \u22658.5%), BMI (\\<30 kg/m\\^2, \u226530 kg/m\\^2) and AHA washout status (Yes, No), and the interaction of time by treatment", "paramType": "Difference in Least Squares Means", "paramValue": "-0.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.5", "ciUpperLimit": "1.2"}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.018", "pValueComment": "Terms for treatment, time, A1C (\\<8.5%, \u22658.5%), BMI (\\<30 kg/m\\^2, \u226530 kg/m\\^2) and AHA washout status (Yes, No), and the interaction of time by treatment", "statisticalMethod": "Longitudinal data analysis", "paramType": "Difference in the Least Squares Means", "paramValue": "-1.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-2.9", "ciUpperLimit": "-0.3"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 12", "description": "This change from baseline reflects the Week 12 FPG minus the Week 0 FPG.", "populationDescription": "All randomized, treated participants with at least one FPG measurement (baseline or post-baseline).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "MK-8521 180 \u03bcg", "description": "Participants receive double-blind MK-8521 180 \u03bcg daily (QD), subcutaneously, over 12 weeks."}, {"id": "OG001", "title": "MK-8521 300 \u03bcg", "description": "Participants receive double-blind MK-8521 300 \u03bcg, QD, subcutaneously, over 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Participants receive matching double-blind placebo QD over 12 weeks."}, {"id": "OG003", "title": "Liraglutide 1.8 mg", "description": "Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "44"}, {"groupId": "OG002", "value": "43"}, {"groupId": "OG003", "value": "42"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-13.7", "lowerLimit": "-27.7", "upperLimit": "0.3"}, {"groupId": "OG001", "value": "-34.6", "lowerLimit": "-49.3", "upperLimit": "-19.9"}, {"groupId": "OG002", "value": "-5.1", "lowerLimit": "-19.4", "upperLimit": "9.2"}, {"groupId": "OG003", "value": "-42.9", "lowerLimit": "-57.0", "upperLimit": "-28.7"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.385", "statisticalMethod": "Longitudinal data analysis", "statisticalComment": "Terms for treatment, time, A1C (\\<8.5%, \u22658.5%), BMI (\\<30 kg/m\\^2, \u226530 kg/m\\^2) and AHA washout status (Yes, No), and the interaction of time by treatment", "paramType": "Difference in Least Squares Means", "paramValue": "-8.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-28.2", "ciUpperLimit": "10.9"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.004", "statisticalMethod": "Longitudinal data analysis", "statisticalComment": "Terms for treatment, time, A1C (\\<8.5%, \u22658.5%), BMI (\\<30 kg/m\\^2, \u226530 kg/m\\^2) and AHA washout status (Yes, No), and the interaction of time by treatment", "paramType": "Difference in Least Squares Means", "paramValue": "29.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "9.7", "ciUpperLimit": "48.6"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.004", "statisticalMethod": "Longitudinal data analysis", "statisticalComment": "Terms for treatment, time, A1C (\\<8.5%, \u22658.5%), BMI (\\<30 kg/m\\^2, \u226530 kg/m\\^2) and AHA washout status (Yes, No), and the interaction of time by treatment", "paramType": "Difference in Least Squares Means", "paramValue": "-29.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-49.6", "ciUpperLimit": "-9.4"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.416", "statisticalMethod": "Longitudinal data analysis", "statisticalComment": "Terms for treatment, time, A1C (\\<8.5%, \u22658.5%), BMI (\\<30 kg/m\\^2, \u226530 kg/m\\^2) and AHA washout status (Yes, No), and the interaction of time by treatment", "paramType": "Difference in Least Squares Means", "paramValue": "8.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-11.7", "ciUpperLimit": "28.2"}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "<0.001", "pValueComment": "Terms for treatment, time, A1C (\\<8.5%, \u22658.5%), BMI (\\<30 kg/m\\^2, \u226530 kg/m\\^2) and AHA washout status (Yes, No), and the interaction of time by treatment", "statisticalMethod": "Longitudinal data analysis", "paramType": "Difference in the Least Squares Means", "paramValue": "-37.8", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-57.5", "ciUpperLimit": "-18.0"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Low Density Lipoprotein (LDL) Cholesterol at Week 12", "description": "This change from baseline reflects the Week 12 fasting LDL cholesterol minus the Week 0 fasting LDL cholesterol.", "populationDescription": "All randomized, treated participants with at least one fasting LDL cholesterol measurement (baseline or post-baseline).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "MK-8521 180 \u03bcg", "description": "Participants receive double-blind MK-8521 180 \u03bcg daily (QD), subcutaneously, over 12 weeks."}, {"id": "OG001", "title": "MK-8521 300 \u03bcg", "description": "Participants receive double-blind MK-8521 300 \u03bcg, QD, subcutaneously, over 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Participants receive matching double-blind placebo QD over 12 weeks."}, {"id": "OG003", "title": "Liraglutide 1.8 mg", "description": "Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "28"}, {"groupId": "OG003", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-9.3", "spread": "23.5"}, {"groupId": "OG001", "value": "8.8", "spread": "41.8"}, {"groupId": "OG002", "value": "4.5", "spread": "33.5"}, {"groupId": "OG003", "value": "0.3", "spread": "18.0"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting High Density Lipoprotein (HDL) Cholesterol at Week 12", "description": "This change from baseline reflects the Week 12 fasting HDL cholesterol minus the Week 0 fasting HDL cholesterol.", "populationDescription": "All randomized, treated participants with at least one fasting HDL cholesterol measurement (baseline or post-baseline).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "MK-8521 180 \u03bcg", "description": "Participants receive double-blind MK-8521 180 \u03bcg daily (QD), subcutaneously, over 12 weeks."}, {"id": "OG001", "title": "MK-8521 300 \u03bcg", "description": "Participants receive double-blind MK-8521 300 \u03bcg, QD, subcutaneously, over 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Participants receive matching double-blind placebo QD over 12 weeks."}, {"id": "OG003", "title": "Liraglutide 1.8 mg", "description": "Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "27"}, {"groupId": "OG001", "value": "26"}, {"groupId": "OG002", "value": "28"}, {"groupId": "OG003", "value": "29"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.4", "spread": "12.3"}, {"groupId": "OG001", "value": "-0.5", "spread": "6.0"}, {"groupId": "OG002", "value": "3.8", "spread": "6.6"}, {"groupId": "OG003", "value": "0.4", "spread": "5.7"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Triglycerides at Week 12", "description": "This change from baseline reflects the Week 12 fasting triglycerides minus the Week 0 fasting triglycerides.", "populationDescription": "All randomized, treated participants with at least one fasting triglycerides measurement (baseline or post-baseline).", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "MK-8521 180 \u03bcg", "description": "Participants receive double-blind MK-8521 180 \u03bcg daily (QD), subcutaneously, over 12 weeks."}, {"id": "OG001", "title": "MK-8521 300 \u03bcg", "description": "Participants receive double-blind MK-8521 300 \u03bcg, QD, subcutaneously, over 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Participants receive matching double-blind placebo QD over 12 weeks."}, {"id": "OG003", "title": "Liraglutide 1.8 mg", "description": "Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "31"}, {"groupId": "OG001", "value": "27"}, {"groupId": "OG002", "value": "31"}, {"groupId": "OG003", "value": "30"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.9", "spread": "91.9"}, {"groupId": "OG001", "value": "-26.6", "spread": "71.2"}, {"groupId": "OG002", "value": "-15.6", "spread": "68.9"}, {"groupId": "OG003", "value": "-20.5", "spread": "48.6"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Systolic Blood Pressure (SBP) at Week 12", "description": "This change from baseline reflects the Week 12 SBP minus the Week 0 SBP.", "populationDescription": "All randomized, treated participants with at least one SBP measurement (baseline or post-baseline).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "MK-8521 180 \u03bcg", "description": "Participants receive double-blind MK-8521 180 \u03bcg daily (QD), subcutaneously, over 12 weeks."}, {"id": "OG001", "title": "MK-8521 300 \u03bcg", "description": "Participants receive double-blind MK-8521 300 \u03bcg, QD, subcutaneously, over 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Participants receive matching double-blind placebo QD over 12 weeks."}, {"id": "OG003", "title": "Liraglutide 1.8 mg", "description": "Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "44"}, {"groupId": "OG002", "value": "43"}, {"groupId": "OG003", "value": "42"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-2.7", "lowerLimit": "-6.4", "upperLimit": "0.9"}, {"groupId": "OG001", "value": "-1.5", "lowerLimit": "-5.2", "upperLimit": "2.3"}, {"groupId": "OG002", "value": "1.0", "lowerLimit": "-2.6", "upperLimit": "4.6"}, {"groupId": "OG003", "value": "-1.7", "lowerLimit": "-5.3", "upperLimit": "2.0"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.151", "statisticalMethod": "Longitudinal data analysis", "statisticalComment": "Terms for treatment, time, A1C (\\<8.5%, \u22658.5%), BMI (\\<30 kg/m\\^2, \u226530 kg/m\\^2) and AHA washout status (Yes, No), and the interaction of time by treatment", "paramType": "Difference in Least Squares Means", "paramValue": "-3.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-8.8", "ciUpperLimit": "1.4"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.682", "statisticalMethod": "Longitudinal data analysis", "statisticalComment": "Terms for treatment, time, A1C (\\<8.5%, \u22658.5%), BMI (\\<30 kg/m\\^2, \u226530 kg/m\\^2) and AHA washout status (Yes, No), and the interaction of time by treatment", "paramType": "Difference in Least Squares Means", "paramValue": "-1.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-6.2", "ciUpperLimit": "4.1"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.344", "statisticalMethod": "Longitudinal data analysis", "statisticalComment": "Terms for treatment, time, A1C (\\<8.5%, \u22658.5%), BMI (\\<30 kg/m\\^2, \u226530 kg/m\\^2) and AHA washout status (Yes, No), and the interaction of time by treatment", "paramType": "Difference in Least Squares Means", "paramValue": "-2.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.7", "ciUpperLimit": "2.7"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.948", "statisticalMethod": "Longitudinal data analysis", "statisticalComment": "Terms for treatment, time, A1C (\\<8.5%, \u22658.5%), BMI (\\<30 kg/m\\^2, \u226530 kg/m\\^2) and AHA washout status (Yes, No), and the interaction of time by treatment", "paramType": "Difference in Least Squares Means", "paramValue": "0.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-5.0", "ciUpperLimit": "5.4"}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.306", "pValueComment": "Terms for treatment, time, A1C (\\<8.5%, \u22658.5%), BMI (\\<30 kg/m\\^2, \u226530 kg/m\\^2) and AHA washout status (Yes, No), and the interaction of time by treatment", "statisticalMethod": "Longitudinal data analysis", "paramType": "Difference in the Least Squares Means", "paramValue": "-2.7", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-7.8", "ciUpperLimit": "2.5"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Diastolic Blood Pressure (DBP) at Week 12", "description": "This change from baseline reflects the Week 12 DBP minus the Week 0 DBP.", "populationDescription": "All randomized, treated participants with at least one DBP measurement (baseline or post-baseline).", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "95% Confidence Interval", "unitOfMeasure": "mmHg", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "MK-8521 180 \u03bcg", "description": "Participants receive double-blind MK-8521 180 \u03bcg daily (QD), subcutaneously, over 12 weeks."}, {"id": "OG001", "title": "MK-8521 300 \u03bcg", "description": "Participants receive double-blind MK-8521 300 \u03bcg, QD, subcutaneously, over 12 weeks."}, {"id": "OG002", "title": "Placebo", "description": "Participants receive matching double-blind placebo QD over 12 weeks."}, {"id": "OG003", "title": "Liraglutide 1.8 mg", "description": "Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "46"}, {"groupId": "OG001", "value": "44"}, {"groupId": "OG002", "value": "43"}, {"groupId": "OG003", "value": "42"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "0.5", "lowerLimit": "-1.7", "upperLimit": "2.8"}, {"groupId": "OG001", "value": "0.4", "lowerLimit": "-1.9", "upperLimit": "2.8"}, {"groupId": "OG002", "value": "-1.0", "lowerLimit": "-3.3", "upperLimit": "1.3"}, {"groupId": "OG003", "value": "0.6", "lowerLimit": "-1.7", "upperLimit": "2.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.347", "statisticalMethod": "Longitudinal data analysis", "statisticalComment": "Terms for treatment, time, A1C (\\<8.5%, \u22658.5%), BMI (\\<30 kg/m\\^2, \u226530 kg/m\\^2) and AHA washout status (Yes, No), and the interaction of time by treatment", "paramType": "Difference in Least Squares Means", "paramValue": "1.5", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.7", "ciUpperLimit": "4.8"}, {"groupIds": ["OG000", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.963", "statisticalMethod": "Longitudinal data analysis", "statisticalComment": "Terms for treatment, time, A1C (\\<8.5%, \u22658.5%), BMI (\\<30 kg/m\\^2, \u226530 kg/m\\^2) and AHA washout status (Yes, No), and the interaction of time by treatment", "paramType": "Difference in Least Squares Means", "paramValue": "-0.1", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.3", "ciUpperLimit": "3.2"}, {"groupIds": ["OG001", "OG002"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.394", "statisticalMethod": "Longitudinal data analysis", "statisticalComment": "Terms for treatment, time, A1C (\\<8.5%, \u22658.5%), BMI (\\<30 kg/m\\^2, \u226530 kg/m\\^2) and AHA washout status (Yes, No), and the interaction of time by treatment", "paramType": "Difference in Least Squares Means", "paramValue": "1.4", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.9", "ciUpperLimit": "4.7"}, {"groupIds": ["OG001", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.905", "statisticalMethod": "Longitudinal data analysis", "statisticalComment": "Terms for treatment, time, A1C (\\<8.5%, \u22658.5%), BMI (\\<30 kg/m\\^2, \u226530 kg/m\\^2) and AHA washout status (Yes, No), and the interaction of time by treatment", "paramType": "Difference in Least Squares Means", "paramValue": "-0.2", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.5", "ciUpperLimit": "3.1"}, {"groupIds": ["OG002", "OG003"], "nonInferiorityType": "SUPERIORITY", "pValue": "0.325", "statisticalMethod": "Longitudinal data analysis", "statisticalComment": "Terms for treatment, time, A1C (\\<8.5%, \u22658.5%), BMI (\\<30 kg/m\\^2, \u226530 kg/m\\^2) and AHA washout status (Yes, No), and the interaction of time by treatment", "paramType": "Difference in the Least Squares Means", "paramValue": "1.6", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-1.6", "ciUpperLimit": "4.9"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "Up to Week 14", "description": "An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure, that occurs during the course of the study. The analysis population included all treated participants.", "eventGroups": [{"id": "EG000", "title": "MK-8521 180 \u03bcg", "description": "Participants receive double-blind MK-8521 180 \u03bcg daily (QD), subcutaneously, over 12 weeks.", "deathsNumAffected": 0, "deathsNumAtRisk": 46, "seriousNumAffected": 0, "seriousNumAtRisk": 46, "otherNumAffected": 18, "otherNumAtRisk": 46}, {"id": "EG001", "title": "MK-8521 300 \u03bcg", "description": "Participants receive double-blind MK-8521 300 \u03bcg, QD, subcutaneously, over 12 weeks.", "deathsNumAffected": 0, "deathsNumAtRisk": 44, "seriousNumAffected": 1, "seriousNumAtRisk": 44, "otherNumAffected": 21, "otherNumAtRisk": 44}, {"id": "EG002", "title": "Placebo", "description": "Participants receive matching double-blind placebo QD over 12 weeks.", "deathsNumAffected": 1, "deathsNumAtRisk": 43, "seriousNumAffected": 1, "seriousNumAtRisk": 43, "otherNumAffected": 15, "otherNumAtRisk": 43}, {"id": "EG003", "title": "Liraglutide 1.8 mg", "description": "Participants receive open-label liraglutide, 1.8 mg QD, subcutaneously, over 12 weeks.", "deathsNumAffected": 0, "deathsNumAtRisk": 42, "seriousNumAffected": 0, "seriousNumAtRisk": 42, "otherNumAffected": 13, "otherNumAtRisk": 42}], "seriousEvents": [{"term": "Chest pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 46}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 44}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 43}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 42}]}, {"term": "Death", "organSystem": "General disorders", "sourceVocabulary": "MedDRA Version 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 46}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 44}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 43}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 42}]}], "otherEvents": [{"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 46}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 44}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 43}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 42}]}, {"term": "Diarrhoea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 5, "numAffected": 4, "numAtRisk": 46}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 44}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 43}, {"groupId": "EG003", "numEvents": 4, "numAffected": 3, "numAtRisk": 42}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 8, "numAffected": 6, "numAtRisk": 46}, {"groupId": "EG001", "numEvents": 10, "numAffected": 7, "numAtRisk": 44}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 43}, {"groupId": "EG003", "numEvents": 12, "numAffected": 9, "numAtRisk": 42}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA Version 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 46}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 44}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 43}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 42}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 7, "numAffected": 6, "numAtRisk": 46}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 44}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 43}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 42}]}, {"term": "Urinary tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA Version 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 46}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 44}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 43}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 42}]}, {"term": "Accidental overdose", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA Version 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 46}, {"groupId": "EG001", "numEvents": 5, "numAffected": 3, "numAtRisk": 44}, {"groupId": "EG002", "numEvents": 3, "numAffected": 3, "numAtRisk": 43}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 42}]}, {"term": "Decreased appetite", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 4, "numAffected": 4, "numAtRisk": 46}, {"groupId": "EG001", "numEvents": 5, "numAffected": 5, "numAtRisk": 44}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 43}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 42}]}, {"term": "Hypoglycaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA Version 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 1, "numAtRisk": 46}, {"groupId": "EG001", "numEvents": 5, "numAffected": 3, "numAtRisk": 44}, {"groupId": "EG002", "numEvents": 2, "numAffected": 1, "numAtRisk": 43}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 42}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 46}, {"groupId": "EG001", "numEvents": 5, "numAffected": 4, "numAtRisk": 44}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 43}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 42}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA Version 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 46}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 44}, {"groupId": "EG002", "numEvents": 5, "numAffected": 4, "numAtRisk": 43}, {"groupId": "EG003", "numEvents": 3, "numAffected": 3, "numAtRisk": 42}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results. Sponsor review can be expedited to meet publication timelines."}, "pointOfContact": {"title": "Senior Vice President, Global Clinical Development", "organization": "Merck Sharp & Dohme Corp.", "email": "ClinicalTrialsDisclosure@merck.com", "phone": "1-800-672-6372"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot_SAP", "hasProtocol": true, "hasSap": true, "hasIcf": false, "label": "Study Protocol and Statistical Analysis Plan", "date": "2016-12-21", "uploadDate": "2018-02-07T16:53", "filename": "Prot_SAP_000.pdf", "size": 2275545}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24", "removedCountries": ["Australia", "Colombia", "Guatemala", "Israel", "New Zealand", "Spain", "United States"]}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type II Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000069450", "term": "Liraglutide"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000097789", "term": "Glucagon-Like Peptide-1 Receptor Agonists"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M419", "name": "Liraglutide", "asFound": "Cessation", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M3401", "name": "Glucagon-Like Peptide-1 Receptor Agonists", "relevance": "LOW"}, {"id": "M9043", "name": "Glucagon", "relevance": "LOW"}, {"id": "M26997", "name": "Glucagon-Like Peptide 1", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Gast", "name": "Gastrointestinal Agents"}]}}, "hasResults": true}